Sheep and Goat BSE Propagate More Efficiently than Cattle BSE in Human PrP Transgenic Mice

Danielle Padilla¹*, Vincent Béringue²*, Juan Carlos Espinosa¹, Olivier Andreoletti³, Emilie Jaumain², Fabienne Reine², Laetitia Herzog², Alfonso Gutierrez-Adan⁴, Belen Pintado⁴, Hubert Laude², Juan Maria Torres¹*

¹ Centro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Spain, ² INRA, UR892, Virologie Immunobiologie Moléculaires, Jouy-en-Josas, France, ³ UMR INRA-ENV'T 1225, Interactions Hôte Agent Pathogène, Ecole Nationale Vétérinaire de Toulouse, Toulouse, France, ⁴ Departamento de Reproducción Animal-INIA, Madrid, Spain

Abstract

A new variant of Creutzfeldt Jakob Disease (vCJD) was identified in humans and linked to the consumption of Bovine Spongiform Encephalopathy (BSE)-infected meat products. Recycling of ruminant tissue in meat and bone meal (MBM) has been proposed as origin of the BSE epidemic. During this epidemic, sheep and goats have been exposed to BSE-contaminated MBM. It is well known that sheep can be experimentally infected with BSE and two field BSE-like cases have been reported in goats. In this work we evaluated the human susceptibility to small ruminants-passaged BSE prions by inoculating two different transgenic mouse lines expressing the methionine (Met) allele of human PrP at codon 129 (tg650 and tg340) with several sheep and goat BSE isolates and compared their transmission characteristics with those of cattle BSE. While the molecular and neuropathological transmission features were undistinguishable and similar to those obtained after transmission of vCJD in both transgenic mouse lines, sheep and goat BSE isolates showed higher transmission efficiency on serial passaging compared to cattle BSE. We found that this higher transmission efficiency was strongly influenced by the ovine PrP sequence, rather than by other host species-specific factors. Although extrapolation of results from prion transmission studies by using transgenic mice has to be done very carefully, especially when human susceptibility to prions is analyzed, our results clearly indicate that Met129 homozygous individuals might be susceptible to a sheep or goat BSE agent at a higher degree than to cattle BSE, and that these agents might transmit with molecular and neuropathological properties indistinguishable from those of vCJD. Our results suggest that the possibility of a small ruminant BSE prion as vCJD causal agent could not be ruled out, and that the risk for humans of a potential goat and/or sheep BSE agent should not be underestimated.

Introduction

Transmissible Spongiform Encephalopathies (TSEs) are fatal neurodegenerative diseases which include Scrapie in sheep and goats, Bovine Spongiform Encephalopathy (BSE) and Creutzfeldt-Jakob disease (CJD) in humans. Prions, the causal agents of these diseases are thought to be infectious protein particles essentially composed of a misfolded isoform (PrPSc) of the cellular prion protein (PrPC) [1,2]. Scrapie has been detected more than two centuries ago, without epidemiological evidence of human transmission. BSE was diagnosed in cattle in the 80s [3] and subsequently acquired epidemic characteristics in several European countries. Ten years later, a variant form of CJD (vCJD) was identified in humans and linked to the consumption of BSE-infected products [4,5]. During the BSE epidemic, sheep and goats have also been exposed to BSE-contaminated Meat and Bone Meal, so BSE transmission to these species may have occurred [6]. Sheep and goats are experimentally susceptible to BSE [7,8,9,10,11] and one confirmed [12] and one suspected [13] BSE-like case have been reported in goats in France and the United Kingdom (UK), respectively. While BSE infection is mostly restricted to the nervous system in cattle [14,15,16,17], PrPSc is widely distributed in lymphoid tissues of experimentally BSE-infected sheep [18,19], suggesting that infected sheep could provide a secondary and more dangerous source of BSE infection for humans.

Considering the protein-only hypothesis, one of the most difficult aspects to explain within prion diseases is the existence of prion strain diversity. Prion strains can be defined as isolates or sources of prion infectivity, that when transmitted to the same host, present distinct disease phenotypes, characterized by their incubation times, clinical signs, PrPSc biochemical properties, histopathological lesion profiles and PrPSc deposition patterns in the brain [20]. Intra-species prion transmission is characterized to be very efficient, maintaining these phenotypic traits on serial subpassaging. Although PrP primary sequence is highly conserved among mammals, inter-species prion propagation is limited by the so called transmission barrier, showing often at first passage lower...
Sheep and Goat BSE Transmission to Human

Author Summary
Prion diseases, also referred to as transmissible spongiform encephalopathies, are fatal neurodegenerative diseases caused by proteinaceous infectious particles denominated “prions.” Prion diseases acquired their first real public relevance with the outbreak of bovine spongiform encephalopathy (BSE) (“mad cow disease”) in the United Kingdom in the 80s and its link with the appearance of a new, variant form of Creutzfeldt-Jakob disease in humans. Recycling of ruminant tissues in meat and bone meal has been proposed as origin of the BSE epidemic. During this episode, sheep and goats have also been exposed to BSE-contaminated meal, so transmission to this species may have occurred. We analyzed the human susceptibility to sheep and goat passed-BSE prions by using transgenic mice expressing human prion protein (PrP). When different sheep and goat BSE isolates were inoculated in these transgenic mice, higher susceptibility than that observed for cattle BSE was detected and the disease manifestation was similar to that observed in mice inoculated with the new variant of Creutzfeldt-Jakob disease. Our findings suggest that humans are at least equally, and might be even more, susceptible to a sheep or goat BSE agent compared to a cattle BSE one.

Low transmission efficiency of cattle-BSE prions in human-PrP mice
Both tg650 and tg340 lines were fairly susceptible to vCJD isolates with 100% clinical attack rates and mean survival times around 500 and 600 days post-infection (d.p.i.), respectively. These features were stable upon subpassaging, suggesting an absence of transmission barrier for this agent (Tables 2 and 3). Inoculation of cattle BSE isolates to tg340 mice produced markedly different results, as previously reported with tg650 mice [36]. At first passage, only one out of fifteen tg340 mice inoculated with BSE2 and BSE4 isolates was scored positive for brain PrPRes and at a very late stage (739 d.p.i.) without clear clinical signs. The remaining inoculated mice failed to develop a clinical disease or to accumulate detectable levels of PrPres in the brain up to ~700 days after inoculation. On second passage performed with brain homogenate from a PrPRes-negative mouse (succeeded at 570 dpi) from the first passage (BSE2 isolate), 3 out of 4 inoculated tg340 mice tested positive for brain PrPRes by western blot with a survival time of 572±37 d.p.i. It is important to note that all the cattle BSE isolates tested in this study were transmitted as efficiently as vCJD isolates or other BSE-related sources to bovine PrP transgenic mice (Table 2 and 3), thus suggesting that they may have a comparable infectivity in the absence of an apparent transmission barrier [36]. Overall, these results indicate that both human-PrP transgenic mouse lines exhibit a strong transmission barrier to cattle BSE, suggesting that human PrP*Met129 is a “bad substrate” for cattle BSE prions.

High transmission efficiency of sheep and goat BSE isolates to human-PrP mice
We next examined the transmission efficiency of sheep- and goat-passaged BSE prions. Several experimental or “natural” isolates of distinct origin were selected (Table 1). Upon primary transmission to both tg340 and tg650 mouse lines, sheep and goat BSE isolates showed significant higher transmission ability than cattle BSE isolates. Thus the attack rates approached 100% (clinical signs, PrPRes detection in the brain) with almost all the sheep and goat BSE isolates used (Tables 2 and 3). Depending on the isolate used, the survival times varied between 371±67 and 749±50 d.p.i. in tg650 and 615±84 - 695±22 in tg340, thus much closer to the survival times observed for vCJD isolates inoculated in these mouse models (Tables 2 and 3). On second and third passage, 100% attack rates were obtained with all the sheep and goat BSE isolates tested. The incubation times were stable or for some isolates, slightly decreased and approached that of variant CJD. Overall, these data suggest a lower or an absence of apparent transmission barrier to sheep and goat BSE in human PrP transgenic mice.

Importantly, the comparatively higher attack rates seen with sheep and goat BSE isolates are not related to their initial PrPRes content as dilution experiment results indicate that cattle BSE isolates (Ga-BSE2 and Ga-BSE3) contained higher PrPRes levels in their brains than the sheep and goat BSE isolates (Figure 1).

Human PrP transgenic mice accumulate vCJD-like PrPRes following inoculation with cattle, sheep or goat BSE
Because distinct PrPRes conformations appear to encipher/encode distinct strains, brain PrPRes electrophyphic mobility and glycoprofile characterization constitutes standard criteria to distinguish
between strains. Brain PrP\textsuperscript{\textastisk} of human PrP tg650 and tg340 transgenic mice inoculated with cattle, sheep and goat BSE isolates were analysed by western blot and the signature obtained was compared to that of variant CJD (Figures 2 and 3). A typical PrP\textsuperscript{\textastisk} banding pattern, characterized by low size fragments (~19 kDa fragment for the aglycosyl band) and prominent diglycosylated species was consistently observed in the challenged, PrPres-positive mice. This signature clearly differed from that observed after inoculation of mice with sporadic CJD (Figure 3 and [35]). Similar results were obtained when the immunoblots were performed with the 12B2 anti-PrP antibody, whose epitope (89WGQGG93 according to the human PrP sequence) is known to be poorly protected from proteinase K digestion [29,37] in vCJD and BSE-related isolates (Figure 4). The only exception was observed after second passage of one cattle BSE isolate (Ca-BSE2) in tg340 mice, one of the three positive mice presented a brain PrPres profile clearly distinct from PrP\textsuperscript{\textastisk}, that was comparable to that of type I sCJD-inoculated tg340 mice with predominantly monoglycosylated and higher size fragments (~21 kDa for the aglycosyl band) and preserved detection by 12B2 antibody (Figure 4).

### Table 1. Description of the different isolates used in this work.

| Isolate     | Origin (case number) | Description and references | Supplier |
|-------------|----------------------|----------------------------|----------|
| Ca-BSE\textsubscript{0} | Fr (139) | BSE naturally infected cow | INRA\textsuperscript{1} |
| Ca-BSE\textsubscript{0}/TgBov | Pool of terminally ill bovine tg110 transgenic mice inoculated with Ca-BSE\textsubscript{0} [17,30] | INIA\textsuperscript{2} |
| Ca-BSE\textsubscript{1} | UK (PG1199/00) | BSE naturally infected cow [51,56] | INRA\textsuperscript{1} |
| Ca-BSE\textsubscript{1}/TgBov | Pool of terminally ill bovine Tg110 transgenic mice inoculated with Ca-BSE\textsubscript{1} [51,56] | INIA\textsuperscript{2} |
| Ca-BSE\textsubscript{2} | Fr (3) | BSE naturally infected cow [43] | INRA\textsuperscript{1} |
| Ca-BSE\textsubscript{3} | Ge | BSE passed in tgXV mice [43] | FLI\textsuperscript{4} |
| Ca-BSE\textsubscript{4} | It (126204) | BSE naturally infected cow [43] | ISS\textsuperscript{5} |
| Ca-BSE\textsubscript{5} | Be | BSE naturally infected cow [43] | LVTSES\textsuperscript{6} |
| Ca-BSE\textsubscript{6} | Fr (ARQ\textsubscript{2}) | Pool of terminally ill ARQ/ARQ sheep inoculated with Ca-BSE\textsubscript{6} [17,30] | INRA\textsuperscript{1} |
| Ca-BSE\textsubscript{7} | Pool of terminally ill bovine Tg110 transgenic mice inoculated with Ca-BSE\textsubscript{7} [17] | INIA\textsuperscript{2} |
| Ca-BSE\textsubscript{8}/TgBov | Pool of terminally ill ARQ/ARQ sheep inoculated with BSE [57] | AFSSA\textsuperscript{7} |
| Ca-BSE\textsubscript{9}/TgBov | ARQ/ARQ sheep inoculated with BSE [57] | AFSSA\textsuperscript{7} |
| Ca-BSE\textsubscript{10} | Fr (CH636) | Goat BSE case [12] | AFSSA\textsuperscript{7} |
| Ca-BSE\textsubscript{11}/TgBov | 2\textsuperscript{nd} passage of bovine tg540 mice inoculated with Go-BSE\textsubscript{1} | INRA\textsuperscript{1} |
| Go-BSE\textsubscript{1} | UK | Goat experimentally infected with BSE | IAH\textsuperscript{9} |
| vCJD\textsubscript{1} | UK (NHBY/0014) | vCJD M129M infected case [58] | NIASC\textsuperscript{10} |
| vCJD\textsubscript{2} | UK (NHBY/0003) | vCJD M129M infected case | NIASC\textsuperscript{10} |
| vCJD\textsubscript{3} | Fr1 | vCJD M129M infected case [35] | INSERM\textsuperscript{11} |
| vCJD\textsubscript{4} | Fr2 | vCJD M129M infected case [35] | INSERM\textsuperscript{11} |
| vCJD\textsubscript{5} | Fr3 | vCJD M129M infected case [35] | INSERM\textsuperscript{11} |
| sCJD\textsubscript{1} | UK (NHBX/0001) | Type I sCJD M129M infected case [58] | NIASC\textsuperscript{10} |

\textsuperscript{1}French National Institute for Agricultural Research (INRA), Nouzilly, France.
\textsuperscript{2}Centro de Investigación en Sanidad Animal– Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (Madrid, Spain).
\textsuperscript{3}Veterinary Laboratory Agency (VLA), New Haw, Addlestone, Surrey, UK.
\textsuperscript{4}provided by Martin Groschup (Friedrich-Loeffler-Institut), Germany.
\textsuperscript{5}National Reference Laboratory for Veterinary TSEs (Belgium).
\textsuperscript{6}National TSE Reference Laboratory (AFSSA, Lyon, France).
\textsuperscript{7}provided by Nora Hunter (IAH, UK).
\textsuperscript{8}Institut National de la Santé et la Recherche Médicale (France).
\textsuperscript{9}doi:10.1371/journal.ppat.1001319.t001

Cattle, sheep and goat BSE isolates showed similar neuropathological features in human PrP mice

The regional distribution of PrP\textsuperscript{\textastisk} and vacuolation in the brains are standard criteria to differentiate between strains/TSE agents [38]. We thus compared the neuropathological phenotypes of cattle, sheep and goat BSE agents by PrPres histoblotting and histopathological examination. The PrP\textsuperscript{\textastisk} deposition pattern of cattle, sheep and goat BSE were clearly similar in both tg650 and tg340 mice on 2\textsuperscript{nd} passage (not shown) and on 3\textsuperscript{rd} passage in tg650. As illustrated in Figure 5, large plaque-like PrP deposits were detected throughout the brain, predominantly in the cerebral cortex, corpus callosum, thalamic nuclei, optic tract, brain stem and cerebellum, a distribution which is similar to that seen in the brains of vCJD-infected tg650 mice (Figure 5 and [35]).

At microscopic level, abundant amyloid-like plaques were present (Figure 6), as suggested by histoblotting. These plaques were associated with severe vacuolation of the surrounding tissue ('florid like' aspect see Figure 6), precluding the establishment of a reliable standard lesion profile. However similar distribution of the vacuolar changes was observed in the brain of mice inoculated...
with the different BSE and the vCJD isolates. It mainly involved thalamic, hippocampal and cerebellar cortex areas, while brainstem and cerebellar cortex remained poorly affected (Figure 6).

**Transmission efficiency of BSE prions into human-PrP mouse models is strongly influenced by the agent PrP primary sequence**

Once known that the phenotypes of cattle, sheep and goat BSE appear indistinguishable in human PrP mice, we proceed to analyze in more detail the potential elements involved in the change on BSE transmission characteristics after passage into sheep or goat. One of the cattle BSE isolate studied (Ca-BSE2) was passaged into bovine (tg110) and ovine PrP transgenic mice (ARQ allele) [39] to propagate BSE agents with different PrP primary sequence (these isolates were termed Ca-BSE2/TgBov and Ca-BSE2/TgOv, Table 1). The Ca-BSE2/TgBov isolate did not induce a clinical disease nor PrP\textsuperscript{Sc} accumulation in tg340 mice while an intermediate passage on the ovine PrP\textsuperscript{ARQ} sequence (Ca-BSE2/TgOv) restored the disease susceptibility, with survival times, biochemical and neuropathological features similar to those obtained with experimental sheep BSE isolates (Figure 7 and data not shown).

The opposite experiment was also performed. One sheep and one goat BSE isolate were passaged (twice for goat BSE) in bovine PrP transgenic mice (generating isolates Sh-BSE0/TgBov and Go-BSE1/TgBov, Table 1) before re-inoculation to human PrP transgenic mice (Figure 7). None of the mice inoculated with these isolates developed the disease nor accumulated PrP\textsuperscript{Sc}, although one of them (Sh-BSE0/tgBov) produced the shortest disease in bovine PrP transgenic mice (Figure 7). This last result suggests that when sheep- or goat-BSE agents recovered their original bovine PrP sequence, the human transmission barrier was re-established. Moreover, the Sh-BSE0/TgOv isolate (which maintains its PrP ovine sequence) showed a full transmission rate in human transgenic mice with similar survival times as those of the original Sh-BSE0 isolate (Figure 7). Overall these data suggest that PrP\textsuperscript{Sc} primary sequence plays a critical role in the capacity of BSE prions to propagate on the human Met 129 PrP sequence.

**Table 2. Transmission of bovine, ovine and goat-BSE isolates to tg650 (INRA).**

| Isolate | Mean survival time in days ± sem (n/n0)\textsuperscript{a} |
|---------|----------------------------------------------------------|
| BoPrP-tg540 mice | HuPrP-tg650 mice |
| 1\textsuperscript{st} passage | 2\textsuperscript{nd} passage | 3\textsuperscript{rd} passage |
| Ca-BSE0 | 298 ± 7 (9/9) \textsuperscript{b} | 872 ± 1 (1/6) \textsuperscript{c} | 568 ± 65 (6/7) \textsuperscript{b} | 527 ± 14 (14/14) |
| Ca-BSE1 | 298 ± 7 (9/9) | 627; 842 (2/6) | 677 ± 54 (7/7) \textsuperscript{b} | 555 ± 24 (8/8) |
| Ca-BSE2 | 269 ± 11 (5/5) \textsuperscript{b} | 802 (1/4) \textsuperscript{b} |
| Ca-BSE4 | 606–775 (0/5) |
| Ca-BSE5 | 360 ± 20 (6/6) \textsuperscript{b} | 696–829 (0/4) |
| Sh-BSE0 | 278 ± 2 (6/6) \textsuperscript{b} | 749 ± 50 (7/8) | 596 ± 21 (8/8) |
| Sh-BSE1 | 339 ± 5 (5/5) | 581 ± 60 (3/3) | 462 ± 21 (5/5) | 518 ± 11 (5/8) \textsuperscript{b} |
| Go-BSE1 | 253 ± 9 (6/6) \textsuperscript{b} | 571 ± 57 (6/5) | 597 ± 16 (9/9) | 534 ± 12 (7/7) |
| Go-BSE2 | 343 ± 98 (5/5) | 736 ± 44 (8/8) |
| vCJD1 | 343 ± 8 (5/5) \textsuperscript{b} | 506 ± 41 (6/10) \textsuperscript{b} | 491 ± 37 (7/7) \textsuperscript{b} | 497 ± 18 (10/10) \textsuperscript{b} |
| vCJD2 | 518 ± 11 (10/10) |
| vCJD3 | 522 ± 18 (5/5) \textsuperscript{b} | 520 ± 26 (7/7) \textsuperscript{b} |
| vCJD4 | 512 ± 15 (8/8) |
| vCJD5 | 515 ± 41 (8/8) |

\textsuperscript{a}Intracerebral inoculation with 2 mg brain tissue equivalent; n/n0, diseased, PrP\textsuperscript{Sc} positive/inoculated animals.
\textsuperscript{b}Data from Beringue et al. [35,36].
\textsuperscript{c}1\textsuperscript{st} passage in hemizygous mice.
\textsuperscript{d}1\textsuperscript{st} passage in hemizygous mice.

**Table 3. Transmission of bovine, ovine and goat-BSE isolates to tg340 (CISA).**

| Isolates | Mean survival time in days ± sem (n/n0)\textsuperscript{a} |
|---------|----------------------------------------------------------|
| BoPrP-tg110 mice | HuPrP-tg340 mice |
| 1\textsuperscript{st} passage | 2\textsuperscript{nd} passage |
| Ca-BSE0 | 303 ± 10 (13/13) \textsuperscript{b} | 739 (1/6) |
| Ca-BSE1 | 308 ± 5 (5/5) \textsuperscript{b} | 491–707 (0/9) | 572 ± 17 (3/4) |
| Sh-BSE0 | 234 ± 5 (16/16) \textsuperscript{b} | 615 ± 84 (4/6) | 564 ± 39 (5/5) |
| Go-BSE1 | 227 ± 3 (7/7) | 695 ± 22 (6/7) |
| vCJD1 | 370 ± 33 (9/9) | 626 ± 29 (6/6) | 612 ± 69 (6/6) |
| sCJD1 | 214 ± 6 (5/5) | 197 ± 6 (7/8) |

\textsuperscript{a}Intracerebral inoculation with 2 mg brain tissue equivalent; n/n0, diseased, PrP\textsuperscript{Sc} positive/inoculated animals.
\textsuperscript{b}Data from Espinosa et al. [29].
\textsuperscript{c}na, not available (experiments still ongoing).
\textsuperscript{d}Ongoing experiment (three animals still alive).

doi:10.1371/journal.ppat.1001319.t003

**Discussion**

In this study, we compared the transmission features of cattle and sheep/goat BSE prions in two different models of transgenic mice expressing Met129 human PrP (tg650 and tg340 lines) in two different laboratories. In general, the transmission results obtained in both human-PrP transgenic mouse lines were very comparable. Some shortening in survival times was observed in tg650 mice (compared to the tg340 mice line), which was probably due to higher PrP expression levels in this line. Worryingly, our results support the view that an intermediate passage of BSE agent in small ruminants accelerates the appearance of a vCJD-like disease in human PrP mice or markedly increases its transmission efficiency. Because the apparent phenotype of cattle and sheep/goat BSE prions is conserved, these data also unravel an important role of PrP\textsuperscript{Sc} primary sequence in the cross-species transmission capacities of prion strains.

The transmission efficiency of cattle BSE isolates in both human-PrP transgenic mouse models was apparently low. With all BSE isolates, whose high infectivity has been demonstrated in bovine-PrP transgenic mice (Tables 2 and 3), very low attack rates were obtained on primary transmission to both tg650 and tg340 mice. Three passages were necessary to achieve a degree of fitness comparable to vCJD in the same mouse line. This low BSE transmission efficiency to human PrP transgenic mice -occasionally accompanied by a strain shift- has also been described by others [40,41,42], and suggests a strong although not absolute transmission barrier. Although the exact characteristics and further evolution of the vCJD epidemic still entail uncertainties owing to prolonged incubation times, this apparent high transmission barrier of humans to cattle BSE might be an explanation for the currently low vCJD incidence, considering the high exposure to BSE during the “mad cow” crisis.
Remarkably, a different picture emerged when the sheep and goat BSE isolates were inoculated to human PrP transgenic mouse models. Attack rates approaching 100% were observed from the primary passage onwards and mean incubation times were more consistent with those measured after transmission of vCJD. On further passaging, the neuropathological phenotype and PrPSc type of cattle and sheep/goat BSE agents appeared indistinguishable from the vCJD agent propagated in these mice, as previously demonstrated in bovine transgenic mice [29], thus strongly supporting the view that the same BSE prion strain has been propagated whatever the infecting species. Hence, these observations reproduced in two distinct human transgenic lines with different genetic background and PrP expression levels support the view that transmission efficiency of BSE prions is increased by an intermediate passage in sheep or goat. Although the electrophoretic pattern of sheep/goat and cattle BSE PrPres appeared similar in human-PrP transgenic mice, other assays are currently performed to further compare the biochemical or biophysical properties of the respective proteins are ongoing.

Importantly, the higher attack rates obtained after sheep and goat BSE transmissions compared to cattle BSE are not in accordance with the initial PrPres content of these isolates. In addition, the data from inoculation to BoPrP-Tg reporter mice suggest that cattle BSE and sheep and goat-BSE isolates could have similar transmission efficiency (Table 1 and 2) in the absence of apparent transmission barrier [36]. Furthermore, when the human PrP transgenic lines were inoculated with the BSE agent passaged into bovine and ovine transgenic mice, the transmission.
results were comparable to those of the cattle and sheep BSE isolates (Figure 7), further supporting the crucial role of the PrPSc primary sequence in the increase of transmission efficiency. Taken together all these considerations suggest that the higher transmission efficiency of sheep and goat BSE isolates in comparison to cattle BSE isolates cannot be linked to a higher infectious titer of the inoculum but must be the outcome of a modification in the pathogenicity of the agent.

Commonly, transmission barriers are determined considering attack rates and quantified by measuring the fall in the mean survival times between the first and second passage. Hence, if we consider PrPres detection as an indicator of successful transmission, our results imply that humans could be significantly more susceptible to a sheep or goat BSE agent than to a cattle BSE agent. On the other hand our results suggest that cattle BSE infection could produce very long latency in humans, with conversion efficiency far below the threshold of detectable PrPres, which is also very worrying since it suggests the possibility of silent carriers.

Our observations, made in two different mouse genetic backgrounds, suggest that the different transmission properties acquired by BSE after passage into either sheep or transgenic mice expressing ovine PrP are strongly related to the ovine PrP primary sequence, rather than to other host species-specific factors. Thus the transmission barrier observed with cattle BSE isolates cannot be linked to a higher infectious titer of the inoculum but must be the outcome of a modification in the pathogenicity of the agent.

The PrP primary sequence influence seems to depend strongly on the strain involved, since no PrPSc was found in either first or second passages of sheep scrapie in tg340 mice (unpublished observations), suggesting no infection, in accordance with the lack of epidemiological evidence linking scrapie with human TSE. Moreover, the low transmission efficiency observed for the cattle BSE agent is not exclusively linked to the bovine PrP sequence since other uncommon BSE strains (BSE-L) are efficiently transmitted to human-PrP mice [41,43]. Considering the conformational selection model [20], our results would suggest that M129 human PrPSc prefers a BSE PrPSc with conformational characteristics templated by the ovine sequence, to a bovine BSE PrPSc. Because a similar increased transmission efficiency of sheep/goat BSE has been reported in wild type mice [44] and transgenic mice expressing elk [45], bovine [29] and porcine [30] PrP, the better structural compatibility conferred by sheep/goat primary PrPSc sequence may not be limited to human PrPSc. One explanation might be an alteration in the quaternary structure (after passage into sheep/goat) generating PrPSc polymers less degraded or more rapidly/easily amplified favouring or enhancing the initial conversion. This question is currently being addressed by sedimentation velocity [46] and PMCA experiments. Another possibility, within the quasispecies concept [20,47], might be that BSE prions confrontation with the sheep and goat primary PrPSc sequence increases the variety of BSE substrain components, with the following emergence of a markedly adapted component in response to the selection pressure imposed by the interspecies transmission events. On the other hand, this component would not be distinguishable from bovine-passaged BSE prions due to the current limits of the standard biological methods and/or the molecular tools employed here to characterize prion strains.
Whatever the mechanism, the notion that a passage through an intermediate species can profoundly alter prion virulence for the human species has important public-health issues, regarding emerging and/or expanding TSEs, like atypical scrapie or CWD.

Although extrapolation of results from prion transmission studies by using transgenic mice has to be done very carefully, especially when human susceptibility to prions is analyzed, our results clearly indicate that Met129 homozygous individuals might be susceptible to a sheep or goat BSE agent at a higher degree than to cattle BSE, and that these agents might transmit with molecular and neuropathological properties indistinguishable from those of vCJD. Although no vCJD cases have been described in Val129 homozygous individuals so far it is relevant to analyze if similar results will be observed in this genotype. This issue is currently being addressed in transmission experiments using transgenic mice expressing Val129 human PrP.

Taken all together, our results suggest that the possibility of a small ruminant BSE prion as vCJD causal agent could not be ruled out, which has important implications on public and animal health policies. On one hand, although the exact magnitude and characteristic of the vCJD epidemic is still unclear, its link with cattle BSE is supported by strong epidemiological ground and several experimental data. On the other hand, the molecular typing performed in our studies, indicates that the biochemical characteristics of the PrP<sup>Sc</sup> detected in brains of our sheep and goat BSE-inoculated mice seem to be indistinguishable from that observed in vCJD. Considering the similarity in clinical manifestation of BSE- and scrapie-affected sheep [48], a masker effect of scrapie over BSE, as well as a potential adaptation of the BSE agent through subsequent passages, could not be ruled out. As BSE infected sheep PrP<sup>Sc</sup> have been detected in many peripheral organs, small ruminant-passaged BSE prions might be a more widespread source of BSE infectivity compared to cattle [19,49,50]. This fact is even more worrying since our transmission studies suggest that apparently Met129 human PrP favours a BSE agent with ovine rather than a bovine sequence. Finally, it is evident that, although few natural cases have been described and so far we cannot draw any definitive conclusion about the origin of vCJD, we can not underestimate the risk of a potential goat and/or sheep BSE agent.

**Materials and Methods**

**Ethics statement**

Animal experiments were carried out in strict accordance with the recommendations in the guidelines of the Code for Methods and Welfare Considerations in Behavioural Research with Animals (Directive 86/609EC) and all efforts were made to minimize suffering. Experiments were approved by the Committee on the
Ethics of Animal Experiments of the author’s institutions (INRA and INIA); Permit Number: RTA06-091 and CT05-036353.

TSE isolates

The isolates used in this study are described in Table 1. For mouse inoculation, all isolated were prepared from brain tissues as 10% (w/v) homogenates in 5% glucose.

Mouse transmission studies

The tg650 transgenic mouse line over expresses human PrP M129 at a 6-fold level on a mouse PrP null background [35]. The tg340 mouse line expressing about 4-fold level of human PrP M129 on a mouse PrP null background has been generated following the same procedure previously described for the generation of other transgenic mouse line expressing different
species PrP [51]. The details of this procedure are described below. Tg110 and tg540 mouse lines express bovine PrP at levels approximately 8-fold that in cattle brain [51,52].

All inocula were prepared from brain tissues as 10% (w/v) homogenates. Individually identified 6–10 week-old mice were anesthetized and inoculated with 2 mg of brain homogenate in the right parietal lobe using a 25-gauge disposable hypodermic needle. Mice were observed daily and the neurological status was assessed weekly. When progression of a TSE disease was evident or at the end of lifespan, animals were euthanized because of ethical reasons. Once euthanized, necropsy was performed and brain was taken. A part of the brain was fixed by immersion in 10% formol to quantify spongiform degeneration by histopathology and PK resistant PrP accumulation (PrP res) by immunohistochemistry (IHQ) or histoblotting and the other was frozen at 2 °C to determine presence of PrPres by Western blot (WB). In all cases, survival time and attack rate were calculated for each isolate. Survival time was expressed as the mean of the survival days post inoculation (d.p.i.) of all the mice scored positive for PrP res, with its correspondent standard error. Attack rate was determined as the proportion of mice scored positive for PrP res from all the mice inoculated. When all mice were scored negative for PrP res on primary passage, PrP res-negative brain homogenates were used for second passage.

Western blot

175±20 mg of frozen brain tissue were homogenized in 5% glucose in distilled water in grinding tubes (Bio-Rad) adjusted to 10% (w/v) using a TeSeETM Precess 48® homogenizer (Bio-Rad) following manufacturer instructions. Presence of PrP res in transgenic mice brains was determined by Western blot, following the procedure described below and using the reagents of the ELISA commercial test (TeSeE, Bio-Rad). 10–50 μl of a 10% (w/v) brain homogenate, to obtain a 200 μl final volume. Homogenates were incubated for 10 min at 37 °C with 200 μl of a 2% proteinase K solution (in buffer A). PrP res was recovered as a pellet after addition of 200 μl of buffer B and a centrifugation at 15,000 × g for 7 min at 20°C. Supernatants were discarded and pellets were dried inverted over absorbent paper for 5 min. Pellets were solubilised in Laemmli buffer and samples were incubated for 5 min at room temperature, solubilised, and heated at 100°C for 5 min. Samples were centrifuged at 20,000 × g for 15 min at 20°C and supernatants were recovered and loaded on a 12% Bis-Tris
Gel (Criterion XT, BioRad or NuPage, Invitrogen). Proteins were electrophoretically transferred onto PVDF or nitrocellulose membranes (Millipore). Membranes were blocked O/N with 2% BSA blocking buffer. For immunoblotting, membranes were incubated with either Sha 31 [53] or 12B2 [37] monoclonal antibody (Mab). Immunocomplexes were detected incubating the membranes for 1 hour with horseradish peroxidase conjugated anti mouse IgG (Amersham Pharmacia Biotech). Immunoblots were developed with enhanced chemiluminescence ECL Plus (GE Healthcare Amersham Biosciences).

Histopathology

All procedures involving mice brains were performed as previously described [54]. Brain slices were realized, in order to allow lesion profiling according to the standard method described by Fraser and Dickinson [55]. Briefly, samples were fixed in neutral-1 buffered 10% formalin (4% 2-formaldehyde) before being cut at determined levels and paraffin embedded. After deparaffinization, 2 µm-thick tissue sections were stained with haematoxylin and eosin.

Histoblots

Brains were rapidly removed from euthanised mice and frozen on dry ice. Thick 8–10 µm cryostat sections were cut, transferred onto Superfrost slides and kept at −20°C until use. Histoblot analyses were performed on 3 brains per infection at 2nd and 3rd passage, using the 3F4 anti-PrP antibody as previously described [35].

Generation of tg340 mouse line expressing human PrP

Tg340 mouse line expressing about 4-fold level of human PrP M129 on a mouse PrP null background has been generated following a similar procedure previously describe for the generation of other transgenic mouse line expressing different species PrP [51,56]. Briefly, the open reading frame (ORF) of human PrP gene was isolated by PCR amplification from human genomic DNA encoding methionine at codon 129. The primers used created a XhoI restriction enzyme site adjacent to the translation start and stop sites of the human PrP ORF (5’- CTCGAGATTATGGCGAACCTTGGCTGCTGG- 3’ and 5’- CTCGAGTCTCCCATCATGAGAGATGAG- 3’, respec-

Figure 8. Brain PrP<sup>C</sup> expression in homozygous tg340 mouse line in comparison to both tg650 mice and human brain. A) Immunoblots of the brain PrP<sup>C</sup> expression in tg340 detected with Pri 308 Mab. Direct sample (10% brain homogenates) and 1/4 dilutions were loaded on 12% Bis-Tris gels. The figure illustrates a representative set of three independent experiments. B) Brain PrP<sup>C</sup> expression in tg340 in comparison to tg650 detected with Pri 308 Mab. Immunoblots illustrates a representative set of three independent experiments and the diagrams represent the mean densyometric values data from these experiments. Data from human brains (Human) were considered as 1 relative unit. Error bars represent the standard deviation of the mean values.

doi:10.1371/journal.ppat.1001319.g008
tively). The PCR fragments obtained were sub cloned into a pGEM-T Easy Vector System (Promega) following manufacturer instructions, and inserts were sequenced to confirm no differences in the inferred amino acid sequence with respect to previously sequenced human PrP genes (GenBank accession number NM_183079) and to confirm the presence of the consequent codon 129 nucleotide variant (Met/Val). The human PrP ORF was excised from the cloning vector using the restriction enzyme XhoI and inserted into the expression vector MoPrP-Xho [51,56]. This vector contains the murine PrP promoter (including exon 1, intron 1, exon 2 and 3′ untranslated sequences) flanked by two XhoI restriction sites but could be distinguished from the wild type murine PrP gene because of the absence of intron 2. The vector was also digested with XhoI to excise the murine PrP ORF and the correspondent human PrP ORF were inserted by ligation, obtaining the plasmid pM0-huPrP129M.Xho.

The human transgene was excised from the plasmid vector using the restriction endonuclease Not I leading to DNA fragments of approximately 12 Kb. Finally, the DNAs were purified and dissolved in TE at a final concentration of 2 to 6 μg/ml and microinjected into pronuclear stage ova collected from superovulated B6CBAF1 females mated with 129/Ola males carrying a null mutation in endogenous PrP [51,56].

DNA from founders’ tails biopsies was extracted using an Extract-N-Amp Tissue PCR kit (Sigma-Aldrich) following manufacturer instructions. The presence of the human transgene in these founders was identified by PCR amplification using specific primers for the mouse PrP exon 2 and human PrP open reading frame. The absence of the murine PrP ORF in the transgenic mice was confirmed by PCR amplification using the primers: 5′-TAGATGTCAGAGGACCTTCAGCC-3′ and 5′-GTCTCACTGATTATGGTACCC-3′. Eight different lines (founders) of human PrP<sup>E</sup> (huPrP) and murine PrP<sup>D</sup> (muPrP) heterogenous transgenic mice (PrP<sup>mu<sup>-/-</sup> hu<sup>+</sup>) were obtained. The expression of human PrP<sup>E</sup> in brain of these mouse lines was analyzed and compared with PrP<sup>E</sup> content in human brain homogenate by western blot using mAb 3F4 which recognizes the 109MKHM<sub>12</sub> epitope (numbered according to the human PrP sequence). Human PrP<sup>E</sup> was detected in 100% of the tested lines (data not shown). From the initial 8 different mouse lines heterogenous for both murine and human PrP genes (PrP<sup>mu<sup>-/-</sup> hu<sup>+</sup>)<sup>-/-</sup>), the mouse line named as tg340 was selected for further experiments on the basis of the level of PrP<sup>E</sup> expression.

Homozygous Tg340 mouse line was established backcrossing these animals with homozygous null animals MuPrP<sup>-/-</sup> (Prnp<sup>-/-</sup>) to obtain a null murine PrP background (PrP<sup>mu<sup>-/-</sup> hu<sup>+</sup>+/-</sup>). Interbreeding within these animals was performed to obtain homozygosity for the human PrP transgen within a murine PrP background (PrP<sup>mu<sup>-/-</sup> hu<sup>+</sup>/+</sup>). The absence of murine PrP gene was determined by PCR using specific primers. Human PrP<sup>E</sup> expression levels, determined more accurately in brain from homozygous tg340 animals was about 4-fold higher than PrP<sup>D</sup> levels in human brain homogenates as determined by dilution experiments in western blot (Figure 8).

**Accession number**

The GenBank accession number for the human Prnp gene used in this paper is NM_183079.

**Acknowledgments**

We thank J. Langeveld for providing 12B2 MAb and the staff of Animalerie Rouges (INRA-Jouy) for excellent mouse care.

**Author Contributions**

Conceived and designed the experiments: VB HL JMT. Performed the experiments: DP VB JCE OA HL JMT. Contributed reagents/materials/analysis tools: HL JMT. Performed the analysis: DP VB JCE OA EJ FR LH AGA BP. Wrote the paper: DP VB OA HL JMT.

**References**

1. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136–144.
2. Griffith JS (1967) Self-replication and scrapie. Nature 215: 1043–1044.
3. Wells GA, Scott AC, Johnson CT, Gunning RF, Hancock RD, et al. (1987) A novel progressive spongiform encephalopathy in cattle. Vet Rec 121: 419-420.
4. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 383: 496–501.
5. Hill AF, Desbruslais M, Jenner S, Siddle KC, Gowland I, et al. (1997) The same murine PrP<sup>−/−</sup> gene used
6. Baylis M, Houston F, Kao RR, McLean AR, Hunter N, et al. (2002) BSE - a wolf in sheep’s clothing? Trends Microbiol 10: 563–570.
7. Foster JD, Hope J, Frazer H (1995) Transmission of bovine spongiform encephalopathy to sheep and goats. Vet Res 153: 339-341.
8. Bellworthy SJ, Dexter G, Stack M, Chaplin M, Hawkins SA, et al. (2005) Natural transmission of BSE between sheep within an experimental flock. Vet Rec 157: 206.
9. Bellworthy SJ, Dexter G, Stack M, Chaplin M, Hawkins SA, et al. (2008) Oral transmission of BSE to VRQ/VRQ sheep in an experimental flock. Vet Rec 162: 130–131.
10. Stack M, Gonzalez L, Jeffrey M, Martin S, Macalowide C, et al. (2009) Three serial passages of bovine spongiform encephalopathy in sheep do not significantly affect discriminatory test results. J Gen Virol 90: 764–769.
11. Houston F, Goldmann W, Chong A, Jeffrey M, Gonzalez L, et al. (2003) Prion diseases: BSE in sheep bred for resistance to infection. Nature 423: 498.
12. Eloit M, Adjou K, Couplier M, Fontaine JG, Hameau R, et al. (2003) BSE agent signatures in a goat. Vet Res 35: 235–247.
13. Jeffrey M, Martin S, Gonzalez L, Foster J, Langeveld JP, et al. (2006) Immunohistochemical features of PrP<sup>D</sup> accumulation in natural and experimental goat transmissible spongiform encephalopathies. J Comp Pathol 134: 171–181.
14. Wells GA, Hawkins SA, Green RB, Austin AR, Dexter I, et al. (1998) Preliminary observations on the pathogenesis of experimental bovine spongiform encephalopathy (BSE): an update. Vet Rec 142: 103–106.
15. Buchmann A, Groschup MH (2005) Highly bovine spongiform encephalopathy-sensitive transgenic mice confirm the essential restriction of infectivity to the nervous system in clinically diseased cattle. J Infect Dis 192: 934–942.
16. Wells GA, Spiraopoulos J, Hawkins SA, Ryder SJ (2005) Pathogenesis of experimental bovine spongiform encephalopathy: preclinical infectivity in tonsil and observations on the distribution of lingual tonsil in slaughtered cattle. Vet Rec 156: 401–407.
17. Espinosa JC, Morales M, Castilla J, Rogers M, Torres JM (2007) Progression of prion infection in asymptomatic cattle after oral bovine spongiform encephalopathy challenge. J Gen Virol 88: 1379–1383.
18. Foster JD, Bruce M, McConnell I, Chree A, Fraser H (1996) Detection of BSE infectivity in brain and spleen of experimentally infected sheep. Vet Rec 139: 546–548.
19. Bellworthy SJ, Hawkins SA, Green RB, Blanire I, Dexter G, et al. (2005) Tissue distribution of bovine spongiform encephalopathy infectivity in Romney sheep up to the onset of clinical disease after oral challenge. Vet Rec 156: 197–202.
20. Collinge J, Clarke AR (2007) A general model of prion strains and their pathogenicity. Science 318: 930–936.
21. Pattison HI (1966) The relative susceptibility of sheep, goats and mice to two types of the goat scrapie agent. Rec Vet Sci 7: 207–212.
22. Scott M, Foster D, Mirandea C, Serbanan D, Goulai F, et al. (1989) Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell 59: 847–857.
23. Prusiner SB, Scott M, Foster D, Pan KM, Groth D, et al. (1996) Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 63: 673–686.
24. Peretz D, Williamson RA, Legname G, Matsunaga Y, Vergara J, et al. (2002) A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron 34: 921–932.
25. Collinge J, Siddle KC, Mears J, Ironside J, Hill AF (1996) Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 383: 685–690.
26. Collinge J, Siddle KC, Mears J, Ironside J, Hill AF (1996) Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 383: 685–690.
27. Scott MR, Perez D, Nguyen HO, Dearmond SJ, Prusiner SB (2005) Transmission barriers for bovine, ovine, and human prions in transgenic mice. J Virol 79: 5259–5271.

28. Nonno R, Di Bari MA, Cardone F, Vaccari G, Fazzi P, et al. (2006) Efficient transmission and clonal expansion of Creutzfeldt-Jakob disease strains in bank voles. PLoS Pathog 2: e12.

29. Espinosa JC, Andreoletti O, Castillo J, Herva ME, Morales M, et al. (2007) Sheep-passaged bovine spongiform encephalopathy agent exhibits altered pathobiological properties in bovine/PrP transgenic mice. J Virol 81: 435–443.

30. Espinosa JC, Herva ME, Andreoletti O, Padilla D, Lacroux C, et al. (2009) Transgenic mice expressing porcine PrP resistant to classical scrapie but susceptible to sheep bovine spongiform encephalopathy and atypical scrapie. Emerg Infect Dis 15: 1214–1221.

31. Palmer MS, Dryden AJ, Hughes JT, Collinge J (1991) Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352: 340–342.

32. Windf O, Denpster M, Ensbflahe JP, Lathe R, de Silva R, et al. (1996) Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene. Hum Genet 98: 259–264.

33. Collinge J (1997) Human prion diseases and bovine spongiform encephalopathy (BSE). Hum Mol Genet 6: 1699–1705.

34. Lee HS, Brown P, Cervenakova L, Garruto RM, Alpers MP, et al. (2001) Increased susceptibility to Kuru of carriers of the PRNP 129 methionine/ methionine genotype. J Infect Dis 183: 192–196.

35. Beringue V, Le Dur A, Tixador P, Reine F, Lepourry L, et al. (2008) Prominent and persistent extraneural infection in human PrP transgenic mice infected with variant CJD. PLoS One 3: e1419.

36. Beringue V, Herzog L, Reine F, Le Dur A, Casalone C, et al. (2008) Transmission of atypical bovine prions to mice transgenic for human prion protein. Emerg Infect Dis 14: 1896–1901.

37. Yull HM, Ritchie DL, Langvey JP, van Zijlveyd FG, Bruce ME, et al. (2006) Detection of type 1 prion protein in variant Creutzfeldt-Jakob disease. Arch Pathol Lab Med 130: 153–157.

38. Fraser H, Dickinson AG (1973) Scrapie in mice. Agent-strain differences in the transmission and distribution of type 1 prion protein in sheep. J Comp Pathol 83: 29–40.

39. Kupfer L, Eiden M, Buschmann A, Groschup MH (2007) Amino acid sequence and prion strain specific effects on the in vitro and in vivo convertibility of ovine/murine and bovine/murine prion protein chimeras. Biochem Biophys Acta 1772: 704–713.

40. Asante EA, Linehan JM, Desbroulais M, Joiner S, Goward L, et al. (2002) BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. Embo J 21: 6339–6346.

41. Kong Q, Zheng M, Casalone C, Qing I, Huang S, et al. (2008) Evaluation of the human transmission risk of an atypical bovine spongiform encephalopathy prion strain. J Virol 82: 3697–3701.

42. Bihof M, Hart P, Aitchison L, Baybutt HN, Plinston G, et al. (2006) Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 5: 393–398.

43. Beringue V, Andreoletti O, Le Dur A, Essalmani R, Villette JL, et al. (2007) A bovine prion acquires an epidemic bovine spongiform encephalopathy strain-like phenotype on interspecies transmission. J Neurosci 27: 6963–6971.

44. Gonzalez L, Chinnani F, Martin S, Siso S, Gibbard L, et al. (2007) Comparative titration of experimental ovine BSE infectivity in sheep and mice. J Gen Virol 88: 714–717.

45. Tamguney G, Miller MW, Giles K, Lemus A, Glidden DV, et al. (2009) Transmission of scrapie and sheep-passaged bovine spongiform encephalopathy prions to transgenic mice expressing elk prion protein. J Gen Virol 90: 1035–1047.

46. Tixador P, Herzog L, Reine F, Jaumain E, Chapuis J, et al. (2010) The physical relationship between infectivity and prion protein aggregates is strain-dependent. PLoS Pathogr 6: e1000859.

47. Li J, Browning S, Mahal SP, Oeschlegel AM, Weissmann C (2010) Darwinian evolution of prions in cells culture. Science 327: 869–872.

48. Baron TG, Madec JY, Calavas D, Richard Y, Barillet F (2000) Comparison of French natural scrapie isolates with bovine spongiform encephalopathy and experimental scrapie infected sheep. Neurosci Lett 284: 175–178.

49. Jeffrey M, Ryder S, Martin S, Hawkins SA, Terry L, et al. (2001) Oral inoculation of sheep with the agent of bovine spongiform encephalopathy (BSE): 1. Onset and distribution of disease-specific PrP accumulation in brain and viscera. J Comp Pathol 124: 280–289.

50. Foster JD, Parnham DW, Hunter N, Bruce M (2001) Distribution of the prion protein in sheep terminally affected with BSE following experimental oral transmission. J Gen Virol 82: 2319–2326.

51. Castilla J, Gutierrez Adan A, Brun A, Pintado B, Ramirez MA, et al. (2003) Early detection of PrPSc in BSE-infected bovine PrP transgenic mice. Arch Virol 148: 677–691.

52. Beringue V, Bencuk A, Le Dur A, Reine F, Lai TL, et al. (2006) Isolation from cattle of a prion strain distinct from that causing bovine spongiform encephalopathy. PLoS Pathog 2: e112.

53. Feraudet C, Morel N, Simon S, Volland H, Frobert Y, et al. (2005) Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J Biol Chem 280: 11247–11256.

54. Andreoletti O, Lacroux C, Chabert A, Monnereau L, Tabouret G, et al. (2002) Detection of type 1 prion protein in variant Creutzfeldt-Jakob disease. Arch Pathol Lab Med 126: 1346–1353.

55. Fraser H, Dickinson AG (1968) The sequential development of the brain lesion of scrapie in mice. Agent-strain differences in the distribution and intensity of grey matter vacuolation. J Comp Pathol 83: 29–40.

56. Castilla J, Gutierrez Adan A, Brun A, Pintado B, Ramirez MA, et al. (2003) Early detection of PrPSc in BSE-infected bovine PrP transgenic mice. Arch Virol 148: 677–691.

57. Jeffrey M, Ryder S, Martin S, Hawkins SA, Terry L, et al. (2001) Oral inoculation of sheep with the agent of bovine spongiform encephalopathy (BSE): 1. Onset and distribution of disease-specific PrP accumulation in brain and viscera. J Comp Pathol 124: 280–289.

58. Cooper JK, Ladhani K, Minor PD (2007) Reference materials for the evaluation of vCJD. Lancet Neurol 5: 393–398.